← Leaderboards
Shahid Nimjee
Basking Biosciences
$3,606,480
Attributed
$4,722,301
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,722,301 · 2
By mechanism
R01$2,490,659 · 1
R44$2,231,642 · 1
Top collaborators
- Richard Joseph Shea2 shared
Others in their field
Other Emerging Leaders on “Fibrinolytic Agents”
- Christina U Lorentz · Aronora, Inc.$4,654,444
- Kenneth B. Bader · University Of Chicago$4,178,329
- Sunil V Rao · Va Puget Sound Healthcare System$4,012,769
- Brian Garriock Firth · Thrombolex, Inc.$2,964,550
- Aditya S Pandey · University Of Michigan At Ann Arbor$2,912,936
- Akhilesh K Sista · New York University School Of Medicine$2,379,135
Research focus
Fibrinolytic AgentsIschemic StrokeCoagulation ProcessFibrinHemorrhageIn VivoBlood PlateletsCessation Of LifeBlood CoagulationErythrocytesFunctional OutcomesAdhesionsImproved OutcomeInnovationArtery OcclusionAlteplaseAffectCerebrumAnimal ModelBindingAcuteDesignAptamerLigands
Grant awards (7)
A Novel Thrombolytic Targeting Von Willebrand Factor (VWF) to Treat Ischemic Stroke$495,141
R01 · FY2025 · NS · contact PI
A novel thrombolytic targeting Von Willebrand Factor (VWF) to treat ischemic stroke$463,641
R01 · FY2024 · NS · contact PI
A novel thrombolytic targeting Von Willebrand Factor (VWF) to treat ischemic stroke$482,054
R01 · FY2023 · NS · contact PI
A novel thrombolytic targeting Von Willebrand Factor (VWF) to treat ischemic stroke$485,810
R01 · FY2022 · NS · contact PI
A reversible aptamer based therapeutic to treat stroke$1,656,236
R44 · FY2021 · HL
A novel thrombolytic targeting Von Willebrand Factor (VWF) to treat ischemic stroke$564,013
R01 · FY2021 · NS · contact PI
A reversible aptamer based therapeutic to treat stroke$575,406
R44 · FY2020 · HL